Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study

Noor Fishan; Kurt Towers; Javier Haurat; Anthony Zimmermann; Anjana Radhakutty

doi:10.1111/imj.16245

Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study

Noor Fishan
, Kurt Towers
, Javier Haurat
, Anthony Zimmermann
, Anjana Radhakutty

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

46 Downloads (Pure)

Abstract

Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have renal and cardiovascular benefits in addition to their glucose-lowering potential. Data on the efficacy and safety of SGLT2i in Australian Aboriginal and Torres-Strait Islanders are lacking. We conducted a single-centre retrospective study assessing the safety and effects on glycaemic control and albuminuria of SGLT2i in Aboriginal and Torres Strait Islander patients with type 2 diabetes mellitus.

Original language	English
Pages (from-to)	1916-1918
Number of pages	3
Journal	Internal Medicine Journal
Volume	53
Issue number	10
DOIs	https://doi.org/10.1111/imj.16245
Publication status	Published - Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aboriginal and Torres Strait Islanders
SGLT2 inhibitor
type 2 diabetes mellitus

Access to Document

10.1111/imj.16245Licence: CC BY-NC-ND

Final published versionFinal published version, 335 KBLicence: CC BY-NC-ND

Cite this

@article{377d00c8b29d452eb07feae4ec721137,

title = "Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study",

abstract = "Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have renal and cardiovascular benefits in addition to their glucose-lowering potential. Data on the efficacy and safety of SGLT2i in Australian Aboriginal and Torres-Strait Islanders are lacking. We conducted a single-centre retrospective study assessing the safety and effects on glycaemic control and albuminuria of SGLT2i in Aboriginal and Torres Strait Islander patients with type 2 diabetes mellitus.",

keywords = "Aboriginal and Torres Strait Islanders, SGLT2 inhibitor, type 2 diabetes mellitus",

author = "Noor Fishan and Kurt Towers and Javier Haurat and Anthony Zimmermann and Anjana Radhakutty",

year = "2023",

month = oct,

doi = "10.1111/imj.16245",

language = "English",

volume = "53",

pages = "1916--1918",

journal = "Internal Medicine Journal",

issn = "1444-0903",

number = "10",

}

Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study. / Fishan, Noor; Towers, Kurt; Haurat, Javier et al.
In: Internal Medicine Journal, Vol. 53, No. 10, 10.2023, p. 1916-1918.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus

T2 - an observational study

AU - Fishan, Noor

AU - Towers, Kurt

AU - Haurat, Javier

AU - Zimmermann, Anthony

AU - Radhakutty, Anjana

PY - 2023/10

Y1 - 2023/10

N2 - Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have renal and cardiovascular benefits in addition to their glucose-lowering potential. Data on the efficacy and safety of SGLT2i in Australian Aboriginal and Torres-Strait Islanders are lacking. We conducted a single-centre retrospective study assessing the safety and effects on glycaemic control and albuminuria of SGLT2i in Aboriginal and Torres Strait Islander patients with type 2 diabetes mellitus.

AB - Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have renal and cardiovascular benefits in addition to their glucose-lowering potential. Data on the efficacy and safety of SGLT2i in Australian Aboriginal and Torres-Strait Islanders are lacking. We conducted a single-centre retrospective study assessing the safety and effects on glycaemic control and albuminuria of SGLT2i in Aboriginal and Torres Strait Islander patients with type 2 diabetes mellitus.

KW - Aboriginal and Torres Strait Islanders

KW - SGLT2 inhibitor

KW - type 2 diabetes mellitus

UR - https://www.scopus.com/pages/publications/85173492615

U2 - 10.1111/imj.16245

DO - 10.1111/imj.16245

M3 - Article

C2 - 37792407

AN - SCOPUS:85173492615

SN - 1444-0903

VL - 53

SP - 1916

EP - 1918

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 10

ER -

Tolerability and efficacy of sodium–glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this